Effectiveness of methylphenidate as augmentation therapy after failure of adjunctive neuromodulation for patients with treatment-refractory bipolar depression: A case report

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 559-562

  Adida, Marc ^a,b   Azorin, Jean Michel ^a,b  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b CNRS   (France)

Author keywords

Bipolar disorder; Depression; Methylphenidate; Neuromodulation refractory; Treatment refractory

Indexed keywords

ARIPIPRAZOLE; CLOMIPRAMINE; CYSTEINE ETHYL ESTER TC 99M; DULOXETINE; FLUOXETINE; METHYLPHENIDATE; MIRTAZAPINE; OLANZAPINE; PAROXETINE; VALPROIC ACID; VENLAFAXINE;

ADULT; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR I DISORDER; BRAIN BLOOD FLOW; CASE REPORT; DAILY LIFE ACTIVITY; DECREASED APPETITE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERANCE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DSM-5; ELECTROCONVULSIVE THERAPY; FOLLOW UP; GUILT; HUMAN; INSOMNIA; MALE; MELANCHOLIA; MIDDLE AGED; MONOTHERAPY; MOOD DISORDER; MORNING DOSAGE; NEUROMODULATION; OPTIMAL DRUG DOSE; PATIENT MONITORING; PSYCHOMOTOR RETARDATION; SELF BLAMING BEHAVIOR; SINGLE DRUG DOSE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUICIDAL IDEATION; THOUGHT DISORDER; VOXEL BASED MORPHOMETRY; WEIGHT REDUCTION;

EID: 84898739967     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S58644     Document Type: Article

References (13)

1. Tohen M, Frank E, Bowden CL, et al. The International Society for Bipolar Disorders (ISBD) Task Force report on the nomenclature of course and outcome in bipolar disorders. Bipolar Disord. 2009;11:453-473.
2. Orr K, Taylor D. Psychostimulants in the treatment of depression: a review of the evidence. CNS Drugs. 2007;21:239-257.
3. Candy M, Jones L, Williams R, Tookman A, King M. Psychostimulants for depression. Cochrane Database Syst Rev. 2008;2:CD006722.
4. Stoll AL, Pillay SS, Diamond L, Workum SB, Cole JO. Methylphenidate augmentation of serotonin selective reuptake inhibitors: a case series. J Clin Psychiatry. 1996;57:72-76.
5. Metz A, Shader RI. Combination of fluoxetine with pemoline in the treatment of major depressive disorder. Int Clin Psychopharmacol. 1991;6:93-96.
6. Stahl SM. Essential Psychopharmacology of Depression and Bipolar Disorder. Cambridge, UK: Cambridge University Press; 2000.
7. Nierenberg AA, Dougherty D, Rosenbaum JF. Dopaminergic agents and stimulants as antidepressant augmentation strategies. J Clin Psychiatry. 1998;59 Suppl 5:60-63.
8. Thase ME, Fava M, DeBattista C, Arora S, Hughes RJ. Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS Spectr. 2006;11:93-102.
9. American Psychiatric Association, DSM-5 Task Force. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Arlington, VA, USA: American Psychiatric Association; 2013.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
11. Guy W. Clinical global impressions. ECDEU Assessment Manual for Psychopharmacology. Rockville, MD, USA: Department of Health, Education, and Welfare; 1976.
12. Stahl SM. Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Application. 3rd ed. New York, NY, USA: Cambridge University Press; 2008.
13. Patkar AA, Masand PS, Pae C-U, et al. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression. J Clin Psychopharmacol. 2006;26:653-656.